ArticleCommunications biology2019
ALK2 inhibitors display beneficial effects in preclinical models of
Open access · goldAbstract read
In one paragraph
Article in Communications biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed
8.6field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 118 citations in OpenAlex.
- Understanding DMG: current treatment options and prospective solutions using nanoparticles.Drug delivery and translational research · 2026Review
- Targeting Activin Receptor-like Kinase 2 Using Heterobifunctional Protein Degraders.Journal of medicinal chemistry · 2026Article
- Improved protein binder design using β-pairing targeted RFdiffusion.Nature communications · 2026Article
- Synergistic antitumor effect of HMGB2 targeting combined with MDM2 inhibitor in diffuse intrinsic pontine glioma therapy.Frontiers in oncology · 2026Article
- Establishment of xenografts and methods to evaluate tumor burden for the three most frequent subclasses of pediatric-type diffuse high grade gliomas.Journal of neuro-oncology · 2025Article
- An oncohistone-driven H3.3K27M/CREB5/ID1 axis maintains the stemness and malignancy of diffuse intrinsic pontine glioma.Nature communications · 2025Article
- Latest Advancements in the Management of H3K27M-Mutant Diffuse Intrinsic Pontine Glioma: A Narrative Review.Cancers · 2025Review
- Discovery of highly potent and ALK2/ALK1 selective kinase inhibitors using DNA-encoded chemistry technology.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in LKB1-Mutant Lung Cancer.Cancer research · 2024Article
- ACVR1/ALK2-p21 signaling axis modulates proliferation of the venous endothelium in the retinal vasculature.Angiogenesis · 2024Article
- Article
- Review
- Discovery of Two Highly Selective Structurally Orthogonal Chemical Probes for Activin Receptor-like Kinases 1 and 2.Journal of medicinal chemistry · 2024Article
- Insights from a multicenter study on adult H3 K27M-mutated glioma: Surgical resection's limited influence on overall survival, ATRX as molecular prognosticator.Neuro-oncology · 2024Article
- Discovery of Conformationally Constrained ALK2 Inhibitors.Journal of medicinal chemistry · 2024Article
- Bone Morphogenic Proteins in Pediatric Diffuse Midline Gliomas: How to Make New Out of Old?International journal of molecular sciences · 2024Review
- PRMT5 inhibition shows in vitro efficacy against H3K27M-altered diffuse midline glioma, but does not extend survival in vivo.Scientific reports · 2024Article
- TP-0184 inhibits FLT3/ACVR1 to overcome FLT3 inhibitor resistance and hinder AML growth synergistically with venetoclax.Leukemia · 2024Article
- BMP signaling in cancer stemness and differentiation.Cell regeneration (London, England) · 2023Review
- Overcoming BCR::ABL1 dependent and independent survival mechanisms in chronic myeloid leukaemia using a multi-kinase targeting approach.Cell communication and signaling : CCS · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 5 institutions in 5 countries.
Diana Carvalho *1Divisions of Molecular Pathology, The Institute of Cancer Research, London, SM2 5NG UK.
Kathryn R Taylor *1Divisions of Molecular Pathology, The Institute of Cancer Research, London, SM2 5NG UK.
Nagore Gene OlacireguiInstitut de Recerca Sant Joan de Deu, Barcelona, 08950 Esplugues de Llobregat Spain.
Valeria Molinari1Divisions of Molecular Pathology, The Institute of Cancer Research, London, SM2 5NG UK.
Matthew Clarke1Divisions of Molecular Pathology, The Institute of Cancer Research, London, SM2 5NG UK.
Alan Mackay1Divisions of Molecular Pathology, The Institute of Cancer Research, London, SM2 5NG UK.
Ruth Ruddle2Division of Cancer Therapeutics, The Institute of Cancer Research, London, SM2 5NG UK.
Alan Henley2Division of Cancer Therapeutics, The Institute of Cancer Research, London, SM2 5NG UK.
Melanie Valenti2Division of Cancer Therapeutics, The Institute of Cancer Research, London, SM2 5NG UK.
Angela Hayes2Division of Cancer Therapeutics, The Institute of Cancer Research, London, SM2 5NG UK.
Alexis De Haven Brandon2Division of Cancer Therapeutics, The Institute of Cancer Research, London, SM2 5NG UK.
Suzanne A Eccles2Division of Cancer Therapeutics, The Institute of Cancer Research, London, SM2 5NG UK.
Florence Raynaud2Division of Cancer Therapeutics, The Institute of Cancer Research, London, SM2 5NG UK.
Aicha Boudhar5Structural Genomics Consortium, University of Oxford, Oxford, OX3 7DQ UK.
Michelle Monje3Stanford University School of Medicine, Stanford, 94305 CA USA.ORCID 0000-0002-3547-237X
Sergey Popov1Divisions of Molecular Pathology, The Institute of Cancer Research, London, SM2 5NG UK.
Andrew S Moore8Diamantina Institute and Child Health Research Centre, The University of Queensland, Brisbane, QLD 4101 Australia.ORCID 0000-0001-8062-1779
Jaume MoraInstitut de Recerca Sant Joan de Deu, Barcelona, 08950 Esplugues de Llobregat Spain.
Ofelia CruzInstitut de Recerca Sant Joan de Deu, Barcelona, 08950 Esplugues de Llobregat Spain.ORCID 0000-0001-7102-3283
Mara Vinci1Divisions of Molecular Pathology, The Institute of Cancer Research, London, SM2 5NG UK.
Paul E Brennan5Structural Genomics Consortium, University of Oxford, Oxford, OX3 7DQ UK.
Alex N Bullock5Structural Genomics Consortium, University of Oxford, Oxford, OX3 7DQ UK.ORCID 0000-0001-6757-0436
Angel Montero CarcabosoInstitut de Recerca Sant Joan de Deu, Barcelona, 08950 Esplugues de Llobregat Spain.ORCID 0000-0002-8485-426X
Chris Jones1Divisions of Molecular Pathology, The Institute of Cancer Research, London, SM2 5NG UK.
Institute of Cancer Research · GBSant Joan de Déu Research Foundation · ESUniversity of Oxford · GBStanford University · USThe University of Queensland · AU
Funding
Cancer Research UK C13468/A14078Wellcome TrustWellcome Trust 106169/ZZ14/Z
Abstract
Diffuse intrinsic pontine glioma (DIPG) is a lethal childhood brainstem tumour, with a quarter of patients harbouring somatic mutations in
Indexed as
Activin Receptors, Type IAdministration, OralAnimalsAntineoplastic AgentsApoptosisBrain Stem NeoplasmsCell Line, TumorCell ProliferationChildDiffuse Intrinsic Pontine GliomaDrug Administration ScheduleDrug Evaluation, PreclinicalFemaleGene ExpressionHigh-Throughput Screening AssaysHumansActivin Receptors, Type IACVR1 protein, humanAntineoplastic AgentsLDN 193189Protein Kinase InhibitorsPyrazolesPyridinesPyrimidinesCNS cancerPaediatric cancerTarget validation
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.